GRI Bio to Present at the 8th Annual IPF Summit
July 01 2024 - 8:45AM
GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a
biotechnology company advancing an innovative pipeline of Natural
Killer T (“NKT”) cell modulators for the treatment of inflammatory,
fibrotic and autoimmune diseases, today announced that Vipin Kumar
Chaturvedi, PhD, Chief Scientific Officer of GRI Bio, will present
at the 8th Annual IPF Summit taking place August 20-22, 2024 in
Boston, MA.
Details of the presentation are as follows:
Title: Examining the Underlying
Mechanism & Patients Subject to the Therapeutic Potential of NK
T-Cell TargetingPresenter: Vipin Kumar Chaturvedi,
PhD, Chief Scientific Officer of GRI BioSession:
Exploring the Clinical Promise of Emerging Modalities & Targets
from NK T-Cells to ADCs, Small RNA Inhibitors, Nanotechnology for
Fibrosis ControlDate and Time: August 22, 2024,
from 8:00-8:30 AM ET
For more information about the event, please
visit the conference website here.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical
company focused on fundamentally changing the way inflammatory,
fibrotic and autoimmune diseases are treated. GRI Bio’s therapies
are designed to target the activity of Natural Killer T (“NKT”)
cells, which are key regulators earlier in the inflammatory
cascade, to interrupt disease progression and restore the immune
system to homeostasis. NKT cells are innate-like T cells that share
properties of both NK and T cells and are a functional link between
the innate and adaptive immune responses. Type I invariant NKT
(“iNKT”) cells play a critical role in propagating the injury,
inflammatory response, and fibrosis observed in inflammatory and
fibrotic indications. GRI Bio’s lead program, GRI-0621, is an
inhibitor of iNKT cell activity and is being developed as a novel
oral therapeutic for the treatment of idiopathic pulmonary
fibrosis, a serious disease with significant unmet need. The
Company is also developing a pipeline of novel type 2 NKT agonists
for the treatment of systemic lupus erythematosus. Additionally,
with a library of over 500 proprietary compounds, GRI Bio has the
ability to fuel a growing pipeline.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the use of words
such as “anticipate,” “believe,” “contemplate,” “could,”
“estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “target,” “aim,” “should,”
“will,” “would,” or the negative of these words or other similar
expressions. These forward-looking statements are based on the
Company’s current beliefs and expectations. Forward-looking
statements include, but are not limited to, statements regarding:
the Company’s expectations with respect to development and
commercialization of the Company’s product candidates, the timing
of initiation or completion of clinical trials and availability of
resulting data, the potential benefits and impact of the Company’s
clinical trials and product candidates and any implication that the
data or results observed in preclinical trials or earlier studies
or trials will be indicative of results of later studies or
clinical trials the Company’s beliefs about the timing and outcome
of regulatory approvals and potential regulatory approval pathways,
. Actual results may differ from the forward-looking statements
expressed by the Company in this press release and consequently,
you should not rely on these forward-looking statements as
predictions of future events. These forward-looking statements are
subject to inherent uncertainties, risks and assumptions that are
difficult to predict, including, without limitation: (1) the
inability to maintain the listing of the Company’s common stock on
Nasdaq and to comply with applicable listing requirements; (2)
changes in applicable laws or regulations; (3) the inability of the
Company to raise financing in the future; (4) the success, cost and
timing of the Company’s product development activities; (5) the
inability of the Company to obtain and maintain regulatory
clearance or approval for its respective products, and any related
restrictions and limitations of any cleared or approved product;
(6) the inability of the Company to identify, in-license or acquire
additional technology; (7) the inability of the Company to compete
with other companies currently marketing or engaged in the
development of products and services that the Company is currently
developing; (8) the size and growth potential of the markets for
the Company’s products and services, and their respective ability
to serve those markets, either alone or in partnership with others;
(9) the failure to achieve any milestones or receive any milestone
payments under any agreements; (10) inaccuracy in the Company’s
estimates regarding expenses, future revenue, capital requirements
and needs for and the ability to obtain additional financing; (11)
the Company’s ability to protect and enforce its intellectual
property portfolio, including any newly issued patents; and (12)
other risks and uncertainties indicated from time to time in the
Company’s filings with the U.S. Securities and Exchange Commission
(the “SEC”), including the risks and uncertainties described in the
“Risk Factors” section of the Company’s most recent Annual Report
on Form 10-K filed with the SEC on March 28, 2024 and subsequently
filed reports. Forward-looking statements contained in this
announcement are made as of this date, and the Company undertakes
no duty to update such information except as required under
applicable law.
Investor Contact:JTC Team, LLCJenene
Thomas(833) 475-8247GRI@jtcir.com
GRI Bio (NASDAQ:GRI)
Historical Stock Chart
From Jul 2024 to Aug 2024
GRI Bio (NASDAQ:GRI)
Historical Stock Chart
From Aug 2023 to Aug 2024